Mechanism of Action of Atropine in Controlling Myopia Progression

October 1, 2020

By Huy Tran, MD, and Thao Ha, MD

Myopia is the most common refractive error worldwide and is estimated to rise to affect about 50 percent of the global population by the year 2050.1 Higher levels of myopia are associated with vision-threatening complications such as retinal detachment, macular degeneration, cataract, and glaucoma.2 Hence, many strategies, i.e., optical, environmental, and pharmaceutical, have been investigated for their ability to slow myopia, and presently, a number of them are widely adopted. Among all the strategies assessed to date, atropine was considered the most effective, and presently, low dose atropine (0.01 percent) is widely used to slow myopia. Despite common use,3 the mechanism underlying the efficacy of atropine in slowing eye growth remains unclear. The aim of this review is to discuss the various hypotheses for the proposed mechanism of action for atropine and present a summary of some of the studies that have been considered so far.

Via the accommodative pathway
Atropine is a nonselective muscarinic antagonist, i.e., it competes for binding sites on all muscarinic receptors, thus blocking the action of acetylcholine. The first use of atropine was based on the hypothesis that excessive accommodative effort caused myopia and atropine abolished the accommodative function. However, landmark studies concluded that it was unlikely atropine was exerting an effect via the accommodative pathway, as both atropine and pirenzepine (another muscarinic antagonist) inhibited myopia in chicks that lack muscarinic receptors in the ciliary muscle, and additionally, myopia could be induced in species that had no functional accommodative system.4, 5 This resulted in a shift away from considering accommodative pathways to exploring pathways in the retina, choroid, and sclera as in most mammalian species, the muscarinic receptors (M1 to M5) are said to be present across these tissues.

Via muscarinic receptor pathways in the retina
It was considered that atropine might be exerting its effect by altering retinal neurotransmission. In chicks, an increased eye length and myopia were found in the presence of damaged retinal ganglion cells, photoreceptors, and amacrine cells6; however, contrary to expectations, ablation of the amacrine cells did not prevent atropine from inhibiting axial elongation.7

Muscarinic receptors are also found in the retinal pigment epithelium, a layer that is involved in transferring the signaling cascade toward the target tissue—i.e., the choroid and/or the sclera.8,9 Atropine was found to increase the release of dopamine but reduced the electroretinogram (ERG) b and d waves and dampened oscillations of retinal pigment epithelium (RPE) potentials. It was suggested that by dampening vital functions of the retina, atropine boosts dopamine release from cellular stores, which then controls eye growth.10 Indeed, in many experimental animal studies, the use of either dopamine or nonselective dopamine receptor agonists was found to inhibit the development of myopia.11,12

Additionally, a study in chicks found strong support for muscarinic antagonists exerting myopia inhibition via M4 receptors that are likely located in the retina.13 These pathways need to be explored further.

Via muscarinic receptor pathways in the choroid
Atropine resulted in rapid and transient choroidal thickening and inhibited eye growth, and it was suggested that the two responses, i.e., choroidal thickening and eye growth, may be linked.14 In more recent studies, administration of 1 percent and even 0.01 percent atropine resulted in an increased sub and para-foveal choroidal thickness. This increase in thickness was considered to be related to either a) blockage of accommodation resulting in less contraction of the choroid; b) loss of excitatory input to the choroidal non-vascular smooth muscle resulting in less contraction, or c) possibly due to the cross-reactivity of atropine resulting in blocking of other receptors such as α-adrenoreceptors.15,16 Furthermore, atropine was found to inhibit choroidal thinning induced by hyperopic defocus.14,17

Via muscarinic receptor pathways in the sclera
There is also a view that sclera is the target site for myopia inhibition with atropine. The synthesis of glycosaminoglycan, of the scleral extracellular matrix, was inhibited by atropine in studies involving scleral tissue from chicks.8 Although atropine was toxic to the scleral chondrocytes at high concentrations, the finding of a reduction of synthesis of glycosaminoglycans opens up another pathway via which atropine may be exerting its effects.

Via other receptors present in the eye
Another consideration is that atropine may be exerting its effect via mechanisms other than blocking muscarinic receptors. The evidence for this comes from multiple lines of investigations. Firstly, only certain muscarinic antagonists inhibit myopia while the majority fail to do so. Other than atropine and pirenzepine, only oxphenonium prevented form-deprivation myopia (FDM) in chicks, whereas compounds, for example, mepenzolate, procyclidine, methoctramine had no effect.8 Secondly, as said previously, atropine was found to affect the glycosaminoglycan synthesis of isolated chicken scleral tissue.8 Additionally, there was cross-reactivity of some muscarinic antagonists with adrenergic receptors. For example, MT3, a muscarinic antagonist, binds not only to muscarinic receptor M4 but also to  α1A-, α 1D-, α 2A-adrenoceptors.18 Also, α2-adrenergic receptors found in human retina19 may also play a role in regulating dopamine synthesis, which affects ocular elongation.11 20

In summary, the mechanism underlying atropine’s efficacy in slowing eye growth is unclear, but it is possible that atropine may be exerting its effect by more than one pathway. An improved understanding of the mechanism and target pathways will provide better ways to administer the compound. Furthermore, knowledge of the mechanism will help identify the individuals who are likely to get better treatment and improve the understanding of potential side effects.




Huy Tran, MD, is a PhD candidate with the Brien Holden Vision Institute, and Thao Ha, MD, is a consulting ophthalmologist with Hai Yen Eye Care in Ho Chi Minh City, Vietnam.




Thao Ha, MD, is an ophthalmologist practicing at Hai Yen Eye Care, Ho Chi Minh City, Vietnam, and is a collaborator of BHVI working on myopia related projects.






  1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006 [published Online First: 2016/02/15]
  2. Saw SM, Gazzard G, Shih-Yen EC, et al. Myopia and associated pathological complications. Ophthalmic Physiol Opt 2005;25(5):381-91. doi: 10.1111/j.1475-1313.2005.00298.x [published Online First: 2005/08/17]
  3. Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology 2019;126(1):113-24. doi: 10.1016/j.ophtha.2018.05.029 [published Online First: 2018/12/06]
  4. Leech EM, Cottriall CL, McBrien NA. Pirenzepine prevents form deprivation myopia in a dose dependent manner. Ophthalmic Physiol Opt 1995;15(5):351-6. [published Online First: 1995/09/01]
  5. McBrien NA, Moghaddam HO, Reeder AP. Atropine reduces experimental myopia and eye enlargement via a nonaccommodative mechanism. Invest Ophthalmol Vis Sci 1993;34(1):205-15. [published Online First: 1993/01/01]
  6. Fischer AJ, Morgan IG, Stell WK. Colchicine causes excessive ocular growth and myopia in chicks. Vision Res 1999;39(4):685-97. doi: 10.1016/s0042-6989(98)00178-3 [published Online First: 1999/05/26]
  7. Fischer AJ, Miethke P, Morgan IG, et al. Cholinergic amacrine cells are not required for the progression and atropine-mediated suppression of form-deprivation myopia. Brain research 1998;794(1):48-60. doi: 10.1016/s0006-8993(98)00188-7 [published Online First: 1998/06/19]
  8. Lind GJ, Chew SJ, Marzani D, et al. Muscarinic acetylcholine receptor antagonists inhibit chick scleral chondrocytes. Invest Ophthalmol Vis Sci 1998;39(12):2217-31. [published Online First: 1998/11/06]
  9. Seko Y, Tanaka Y, Tokoro T. Apomorphine inhibits the growth-stimulating effect of retinal pigment epithelium on scleral cells in vitro. Cell biochemistry and function 1997;15(3):191-6. doi: 10.1002/(sici)1099-0844(199709)15:3<191::aid-cbf738>;2-2 [published Online First: 1997/10/23 22:34]
  10. Schwahn HN, Kaymak H, Schaeffel F. Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick. Vis Neurosci 2000;17(2):165-76. doi: 10.1017/s0952523800171184 [published Online First: 2000/05/29]
  11. Schaeffel F, Bartmann M, Hagel G, et al. Studies on the role of the retinal dopamine/melatonin system in experimental refractive errors in chickens. Vision Res 1995;35(9):1247-64. doi: 10.1016/0042-6989(94)00221-7 [published Online First: 1995/05/01]
  12. Dong F, Zhi Z, Pan M, et al. Inhibition of experimental myopia by a dopamine agonist: different effectiveness between form deprivation and hyperopic defocus in guinea pigs. Molecular vision 2011;17:2824-34. [published Online First: 2011/12/01]
  13. McBrien NA, Arumugam B, Gentle A, et al. The M4 muscarinic antagonist MT-3 inhibits myopia in chick: evidence for site of action. Ophthalmic Physiol Opt 2011;31(5):529-39. doi: 10.1111/j.1475-1313.2011.00841.x [published Online First: 2011/05/05]
  14. Nickla DL, Zhu X, Wallman J. Effects of muscarinic agents on chick choroids in intact eyes and eyecups: evidence for a muscarinic mechanism in choroidal thinning. Ophthalmic and Physiological Optics 2013;33(3):245-56.
  15. Sander BP, Collins MJ, Read SAJEer. The effect of topical adrenergic and anticholinergic agents on the choroidal thickness of young healthy adults. 2014;128:181-89.
  16. Zhang Z, Zhou Y, Xie Z, et al. The effect of topical atropine on the choroidal thickness of healthy children. 2016;6(1):1-8.
  17. Chiang ST-H, Phillips JRJJoo. Effect of atropine eye drops on choroidal thinning induced by hyperopic retinal defocus. 2018;2018
  18. Näreoja K, Kukkonen JP, Rondinelli S, et al. Adrenoceptor activity of muscarinic toxins identified from mamba venoms. Br J Pharmacol 2011;164(2b):538-50. doi: 10.1111/j.1476-5381.2011.01468.x [published Online First: 2011/05/12]
  19. Woldemussie E, Wijono M, Pow D. Localization of alpha 2 receptors in ocular tissues. Visual neuroscience 2007;24(5):745-56. doi: 10.1017/s0952523807070605 [published Online First: 2007/11/08]
  20. Iuvone PM, Rauch AL. Alpha 2-adrenergic receptors influence tyrosine hydroxylase activity in retinal dopamine neurons. Life Sci 1983;33(24):2455-63. doi: 10.1016/0024-3205(83)90640-9 [published Online First: 1983/12/12]
To Top